SlideServe
Menu
Préférences
© SlideServe · v2026

Pharmaceutical R&D Process – Why d o Clinical T rials F ail ?

constance-wilkerson avatar
13 diapositives · 308 Views · Nov 20, 2014

Pharmaceutical R&D Process – Why d o Clinical T rials F ail ?. Erika Buonansegna, PhD Student DTU Management Engineering Supervisors: Søren Salomo , DTU Management Engineering Anja Maier, DTU Management Engineering Jason Li-Ying , DTU Management Engineering

Pharmaceutical R&D Process – Why d o Clinical T rials F ail ? - slide 1
01 / 13Pharmaceutical R&D Process – Why d o Clinical T rials F ail ?
1 / 17

Télécharger la présentation

Pharmaceutical R&D Process – Why d o Clinical T rials F ail ?
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation
  1. Pharmaceutical R&D Process –Why do Clinical Trials Fail? Erika Buonansegna, PhD Student DTU Management Engineering Supervisors: SørenSalomo, DTU Management Engineering Anja Maier, DTU Management Engineering Jason Li-Ying, DTU Management Engineering Carsten Schultz, Kiel University, Germany Collaborating partner: Medidata Solutions, Inc., New York

  2. gate gate gate gate P.I.R Market Approval Clinical Trials 2

  3. INTRO TO THE PHARMACETICAL R&D: DRUG DISCOVERY AND DEVELOPMENT PROCESS 0.5-2 years 6-7 years 3-6 years Market Approval Clinical Trials 250 5 5.000-10.000 compounds 1 (Efpia, 2011)

  4. CLINICAL TRIAL NETWORK Sponsor Site

  5. CLINICAL TRIAL NETWORK Sponsor CRO Site

  6. CLINICAL TRIAL NETWORK Sponsor CRO Site

  7. RESEARCH MOTIVATION • Few studies on CT failure • Little knowledge on determinants of failure in late development stages • Search for tools to manage CTs Reasons for drug failure (Centre for Medicine Research in Kennedy, 1997) (DiMasi, 2001)

  8. RESEARCH AIM AND QUESTIONS Refine the understanding on failures in clinical trials as a late development stage. Research Questions: • “What causes failure of clinical trials?” • “Can such causes be systematically mapped?” • “Does the assessment of clinical trial failures provide insights into a more general concept of NPD failure during later stages of the development process?”

  9. METHODOLOGY Address clinical trials specificities Literature review Expert study 17 interviews Conceptual framework

  10. Not potential product Potential product CONCEPTUAL FRAMEWORK Completion of a project Termination of a project

  11. MANAGERIAL IMPLICATIONS Proactive strategies • Improving skills of the development team • Due diligence in choosing sites and subcontractors • E-recruitment tactics • Monitoring sites and subcontractors • Interim and risk analyses • Training for SAEs • Feedback from investigators Reactive strategies • Fast reallocation of resources • Back-up candidates and parallel-track strategy • Learning-by-failing mind set

  12. FUTURE RESEARCH • Clinical trial research • Interdependencies • Ranking according to phases • In-depth case studies • Late development stages in other industries

  13. Erika Buonansegna PhD Student Technical University of Denmark DTU Management Engineering Produktionstorvet, Bygning 426 2800 Kgs. Lyngby Denmark erbou@dtu.dk